Phase I Investigational Group
Our Mission
Our priority is to provide investigational agents that are supported by strong experimental and preclinical data to a patient population for which standard therapy is ineffective. We care for our patients with compassion, and we respect their courageous volunteerism to participate in clinical research. We are committed to maintaining the integrity of scientific research through the Dana-Farber/Harvard Cancer Center and contributing to the future of cancer therapeutics.
Who Are We?
Director: Bruce Dezube M.D.
Associate Director: Susan Pandya M.D.
Research Nurse: Sue Gotthardt RN, OCN
Project Manager: Myles Clancy
Clinical Research Assistant: Janine Morrissey
Clinical Research Assistant: Brian Rowley
Administrative Assistant: Rena Flambo
Phase I Clinical Trials
As members of the Dana-Farber/Harvard Cancer Center (DF/HCC), the Phase I Investigational Group offers several agents with various mechanisms of action. The list of options varies and is updated accordingly. Please contact Sue Gotthardt RN, OCN at (617) 632-9272 for more information.
